On Tuesday, Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) was -0.15% drop from the session before settling in for the closing price of $20.05. A 52-week range for KNSA has been $16.87 – $28.15.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 110.12% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 213.62%. With a float of $40.43 million, this company’s outstanding shares have now reached $41.88 million.
In an organization with 315 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 85.54%, operating margin of -10.78%, and the pretax margin is -8.54%.
Kiniksa Pharmaceuticals International Plc (KNSA) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Kiniksa Pharmaceuticals International Plc stocks. The insider ownership of Kiniksa Pharmaceuticals International Plc is 44.57%, while institutional ownership is 56.31%. The most recent insider transaction that took place on Apr 21 ’25, was worth 370,422. Before that another transaction happened on Apr 14 ’25, when Company’s CHIEF OPERATING OFFICER sold 12,000 for $20.48, making the entire transaction worth $245,812. This insider now owns 77,363 shares in total.
Kiniksa Pharmaceuticals International Plc (KNSA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 213.62% per share during the next fiscal year.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) Trading Performance Indicators
You can see what Kiniksa Pharmaceuticals International Plc (KNSA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.45. Likewise, its price to free cash flow for the trailing twelve months is 57.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 1.24 in one year’s time.
Technical Analysis of Kiniksa Pharmaceuticals International Plc (KNSA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.65 million. That was better than the volume of 0.62 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 60.63%. Additionally, its Average True Range was 1.04.
During the past 100 days, Kiniksa Pharmaceuticals International Plc’s (KNSA) raw stochastic average was set at 33.90%, which indicates a significant decrease from 44.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.21% in the past 14 days, which was higher than the 40.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.05, while its 200-day Moving Average is $22.53. However, in the short run, Kiniksa Pharmaceuticals International Plc’s stock first resistance to watch stands at $20.43. Second resistance stands at $20.85. The third major resistance level sits at $21.25. If the price goes on to break the first support level at $19.61, it is likely to go to the next support level at $19.21. The third support level lies at $18.79 if the price breaches the second support level.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) Key Stats
There are 72,644K outstanding shares of the company, which has a market capitalization of 1.46 billion. As of now, sales total 423,240 K while income totals -43,190 K. Its latest quarter income was 122,540 K while its last quarter net income were -8,890 K.
